Close Navigation
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
Overlay

Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia

19th October 2020

Useful Tools

Download, print or share this article

Print Print Article Email Email Article
Print Save Article
Share Article
TwitterTwitterLinkedInLinkedInFacebookFacebook